Tyra Biosciences carries $47.40 analyst target despite wider loss
Alpha Vantage · MarketBeat · · AI-summarised by FinFlash
Analysts hold a "Moderate Buy" consensus on Tyra Biosciences (NASDAQ:TYRA) with an average one-year price target of $47.40, implying roughly 140% upside from the Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.Understand the context